The Hackett Group (HCKT) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
23 Dec, 2025Executive summary
Q4 2024 revenue was $79.2 million, with adjusted EPS of $0.47, both exceeding guidance, driven by strong SAP and GenAI segment performance.
Acquisition of LeewayHertz and the launch of a GenAI-focused joint venture (ZBrain) are expected to drive future growth and expand GenAI consulting capabilities.
Sequential and year-over-year revenue growth was achieved, with improved advisory program sales and renewals.
Adjusted diluted EPS was $0.47, while GAAP diluted EPS was $0.12, impacted by non-cash compensation and acquisition expenses.
Financial highlights
Q4 2024 total revenue was $79.2 million; revenue before reimbursements was $77.5 million, above guidance.
Adjusted EBITDA was $19.5 million (25.2% of revenues before reimbursements), up from $16.3 million (23%) YoY.
Adjusted net income was $13.6 million, or $0.47 per share, up from $0.39 per share YoY.
GAAP net income was $3.6 million ($0.12 per share), down from $7.9 million ($0.28 per share) YoY, impacted by stock compensation and acquisition expenses.
Cash balance at quarter end was $16.4 million, up from $10 million in the prior quarter.
Outlook and guidance
Q1 2025 revenues before reimbursements expected at $75.0–$76.5 million.
Q1 2025 adjusted diluted EPS guidance is $0.39–$0.41, assuming a 22% GAAP tax rate.
Global S&BT segment revenue expected to grow 5–10% YoY, driven by GenAI, offset by declines in OneStream and e-procurement.
Oracle and SAP segments combined expected to decline 8–10% YoY in Q1.
Adjusted gross margin expected at 43–44%; adjusted EBITDA margin at 21–22%.
Latest events from The Hackett Group
- Annual meeting to vote on director, stock plan amendment, compensation, and auditor ratification.HCKT
Proxy filing20 Mar 2026 - Proxy covers director election, compensation, stock plan amendment, and auditor ratification.HCKT
Proxy filing20 Mar 2026 - Q4 2025 beat guidance with SAP and GenAI gains, but margins and EBITDA declined year-over-year.HCKT
Q4 202517 Feb 2026 - Q2 revenue and EPS exceeded guidance, with Gen AI investments and strong cash flow.HCKT
Q2 20242 Feb 2026 - Q3 revenue and adjusted EPS beat guidance; GenAI growth accelerated by LeewayHertz acquisition.HCKT
Q3 202417 Jan 2026 - Shareholders will vote on director elections, stock plan expansion, executive pay, and auditor ratification.HCKT
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, stock plan amendment, compensation, and auditor.HCKT
Proxy Filing2 Dec 2025 - Q2 revenue up 1.6% to $78.9M; Gen AI drives growth, but costs weigh on net income.HCKT
Q2 202523 Nov 2025 - GenAI-fueled growth drove strong Q1 results, despite lower net income from higher expenses.HCKT
Q1 202521 Nov 2025